Exhibit 99.1

                                           Investor Inquiries:
                                           Robert Gudbranson
                                           Director of Investor Relations
                                           (440) 329-6001

                                           Media Inquiries:
                                           Susan Elder
                                           Director of Marketing Communications
                                           (440) 329-6549

News Release

INVACARE CORPORATION ANNOUNCES REGULATORY APPROVAL ON ACQUISITION OF
WP DOMUS GMBH.

         ELYRIA, OH - September 1, 2004 - Invacare Corporation (NYSE: IVC)
announced today that the Company has received regulatory approval in both
jurisdictions that were reviewing the Company's proposed acquisition of WP Domus
GmbH ("Domus"), which was announced August 2, 2004. Norwegian authorities did
not raise any issues during the review period and thereby allowed the
transaction to proceed. German authorities confirmed today, following their
review, that the transaction could proceed. Invacare will work with the Seller
of Domus with a view to closing the transaction by the end of next week.

Invacare Corporation (NYSE:IVC), headquartered in Elyria, Ohio, is the global
leader in the manufacture and distribution of innovative home care and long-term
care medical products that promote recovery and active lifestyles. The Company
has 5,300 associates and markets its products in 80 countries around the world.
For more information about the Company and its products, visit Invacare's
website at www.invacare.com.


This press release contains forward-looking statements within the meaning of the
"Safe Harbor" provisions of the Private Securities Litigation Reform Act of
1995. Terms such as "will," "should," "plan," "intend," "expect," "continue,"
"believe," "anticipate" and "seek," as well as similar comments, are
forward-looking in nature. Actual results and events may differ significantly
from those expressed or anticipated as a result of risks and uncertainties which
include, but are not limited to, the following: pricing pressures, the success
of the Company's ongoing efforts to reduce costs, increasing raw material costs,
the consolidations of health care customers and competitors, government
reimbursement issues (including those that affect the sales of and margins on
product, along with the viability of customers), the ability to design,
manufacture, distribute and achieve market acceptance of new products with
higher functionality and lower costs, the effect of offering customers
competitive financing terms, Invacare's ability to successfully identify,
acquire and integrate strategic acquisition candidates, the difficulties in
managing and operating businesses in many different foreign jurisdictions
(including the Domus acquisition, if completed), the timely completion of
facility consolidations, the vagaries of any litigation or regulatory
investigations that the Company may be or become involved in at any time
(including the previously-disclosed litigation with Respironics), the
difficulties in acquiring and maintaining a proprietary intellectual property
ownership position, the overall economic, market and industry growth conditions
(including the impact that acts of terrorism may have on such growth
conditions), foreign currency and interest rate risks, Invacare's ability to
improve financing terms and reduce working capital, as well as the risks
described from time to time in Invacare's reports as filed with the Securities
and Exchange Commission. We undertake no obligation to review or update these
forward-looking statements or other information contained herein.
                                    ###